GlassScriptPhysician profile
Shaun Donegan
NPI 1104038249
$16,839.38
in general payments reported to CMS, 2019-2025
79 companies · $3,293 in 2025
The $3,293 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,952 · 2020: $1,697 · 2021: $2,097 · 2022: $2,435 · 2023: $2,335 · 2024: $3,030 · 2025: $3,293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,658.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,658.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,720.99 | 2019-2025 | Imfinzi, Enhertu, Calquence |
| Novartis Pharmaceuticals Corporation | $1,144.45 | 2019-2025 | |
| Janssen Biotech, INC. | $1,080.39 | 2019-2025 | Erleada, Darzalex, Tecvayli |
| Merck Sharp & Dohme LLC | $1,038.24 | 2019-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $842.63 | 2019-2025 | Opdivo, Opdualag |
| Pfizer INC. | $675.52 | 2019-2025 | |
| Eisai INC. | $622.42 | 2019-2025 | |
| Genentech USA, INC. | $564.39 | 2019-2025 | Lunsumio, Hemlibra, Tecentriq |
| Incyte Corporation | $554.05 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Astellas Pharma US INC | $546.41 | 2020-2025 | Xtandi, Padcev, Vyloy |
| Abbvie INC. | $497.79 | 2019-2025 | Venclexta |
| Genzyme Corporation | $459.35 | 2019-2025 | |
| Amgen INC. | $442.66 | 2019-2023 | Kyprolis, Nplate, Xgeva |
| Daiichi Sankyo INC. | $369.57 | 2019-2025 | Enhertu, Vanflyta, Injectafer |
| Exelixis INC. | $367.43 | 2019-2025 | Cabometyx |
Show all 79 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaun Donegan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.